In this week’s edition of InnovationRx, we delve into BillionToOne’s IPO, China’s biotech power couple, and Lilly’s eye drug deal. To receive it directly in your inbox, subscribe here.
A bipartisan agreement may put an end to the government shutdown, but it neglected to address subsidies for health insurance coverage under the Affordable Care Act, a key demand from Democrats. These tax credits aim to keep ACA plans affordable and are set to expire at the end of the year.
The deal was struck after eight Democratic Senators broke ranks to reopen the government following the longest shutdown in history. The Senate approved its bill on Monday, with the House likely to vote later today.
Approximately 22 million individuals, representing 92% of those enrolled in ACA marketplace plans, benefit from these enhanced subsidies. If these subsidies were to expire, monthly premium payments could more than double on average, increasing by about 114%. Those in red states that did not expand Medicaid coverage would be particularly affected.
If more people opt out of health insurance due to cost, it could lead to increased emergency room visits, negatively impacting care and raising costs for the healthcare system. Additionally, if younger, healthier individuals choose to forgo coverage, rates could escalate even more for those who remain insured.
The Democratic faction received a commitment for a vote in December on extending the tax credits for a year, but the bill’s fate in a Republican-led Congress seems uncertain. Speaker of the House Mike Johnson has not promised a vote, and President Trump has long advocated for replacing Obamacare, even suggesting direct cash payments to individuals instead of funneling money through insurance companies.
For more details on these developments, read here.
How A Turkish Immigrant Engineered A Successful Diagnostics Startup IPO
Oguzhan Atay, a Turkish immigrant with a Ph.D. in systems biology from Stanford University, founded BillionToOne in 2016. The company, based in Menlo Park, California, went public on the Nasdaq stock exchange last week, raising $273 million. By the end of trading, its shares surged over 80%, reaching a market cap of $5.8 billion.
BillionToOne has rapidly expanded its business, offering noninvasive prenatal genetic tests and cancer testing. It generated $209 million in revenue in the last 12 months and has shown steady growth. Although the company is currently operating at a loss, Atay remains optimistic about its future prospects.
China’s Richest Self-Made Woman Amassed A $20 Billion Fortune From Biotech
Zhong Huijan, chairman and CEO of Hansoh Pharmaceuticals, has become China’s wealthiest self-made woman with a net worth of $19.8 billion. Her success stems from strategic licensing deals with major pharmaceutical companies like Roche, GSK, and Merck. Alongside her husband Sun Piaoyang, chairman of Jiangsu Hengrui Pharmaceuticals, the couple has built a formidable presence in China’s biotech industry.
Deal of the Week
Eli Lilly has agreed to license a gene therapy from MeiraGTx, a New York-based biotech company, for up to $475 million. A clinical trial successfully restored vision to all 11 patients with a rare genetic condition causing legal blindness. MeiraGTx, a publicly traded company with a market cap over $700 million, secured an exclusive license for the treatment, receiving $75 million upfront with additional payments linked to regulatory and development milestones. This agreement also grants Lilly exclusive access to MeiraGTx’s technology for potential vision disorder treatments. Forbes previously featured MeiraGTx in a profile earlier this year. Please rephrase this sentence.
